Published in
BMJ Publishing Group, Journal of Neurology, Neurosurgery and Psychiatry, 11(87), p. 1183-1190, 2016
Links
- ORCID
- ORCID
- ORCID
- BMJ Publishing Group
- [orca.cf.ac.uk] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [research-information.bristol.ac.uk] | PDF
- [europepmc.org] | PDF
- [aura.abdn.ac.uk] | PDF
- [eprints.gla.ac.uk] | PDF
- [orca.cf.ac.uk] | PDF
- [discovery.ucl.ac.uk] | PDF
- [lup.lub.lu.se] | PDF
- [research-information.bristol.ac.uk] | PDF
Tools
Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts
,
Katherine A. Grosset,
Naveed Malek,
Johannes Klein,
Fahd Baig,
Claudio Ruffmann,
Nin P. Bajaj,
Roger A. Barker,
Yoav Ben-Shlomo ,
David J. Burn,
Thomas Foltynie,
Huw R. Morris,
Nigel Williams,
Nicholas W. Wood
and other authors.
Full text: Download
Abstract
Background Cardiovascular disease (CVD) influences phenotypic variation in Parkinson’s disease (PD), and is usually an indication for statin therapy. It is less clear whether cardiovascular risk factors influence PD phenotype, and if statins are prescribed appropriately. Objectives To quantify vascular risk and statin use in recent-onset PD, and examine the relationship between vascular risk, PD severity and phenotype. Methods Cardiovascular risk was quantified using the QRISK2 calculator (high ≥20%, medium ≥10 and